GLP-1 clinical workshop recap: 5 takeaways from Dr. Mahnaz Qayyum

The clinical applications of GLP-1 receptor agonists keep expanding (obesity, type 2 diabetes, and obstructive sleep apnea), and so do the questions from both patients and providers.

Dr. Mahnaz Qayyum recently joined the Evitalin team for an Online Clinic covering practical prescribing protocols, patient management strategies, and how to build a sustainable weight management practice utilizing these medications.

Here are five takeaways from Dr. Qayyum’s event worth highlighting.

GLP-1 benefits extend well beyond weight loss

Anyone who has heard the term “GLP-1” knows they can produce significant weight loss. As Dr. Qayyum noted, clinical data shows patients can lose 15 to 20% of their body weight over six to 12 months.

What makes these drugs remarkable is everything that follows from that loss.

“So many other body systems are affected,” Dr. Qayyum noted during the session. “It’s absolutely incredible.”

When you prescribe a GLP-1 for weight loss, you are simultaneously addressing cardiovascular risk, metabolic liver disease, kidney function, and inflammatory burden. That multi-system value is a conversation worth having with every patient.

Patient education separates good outcomes from mediocre ones

The most effective pharmacologic therapy for obesity still requires a clinical relationship to produce lasting results. Dr. Qayyum was direct about this.

“I had patients, especially in the beginning when I first started, they’ll just take the drug and they don’t do anything,” she said. “Or they’ll do strange things like not eating for 19 hours.”

Dr. Qayyum’s approach keeps education simple and actionable.

She recommends approximately 25 grams of protein per meal, no skipped meals, structured intermittent fasting (such as no eating after 7 PM), and a consistent exercise regimen.

“If you make it overly complicated, patients get a little bit overwhelmed,” she explained. “Give the information one small bite at a time.”

Patients now have more price benchmarks than ever. TrumpRx lists Wegovy pens starting at $199/month and Wegovy pills at $149/month, and branded tirzepatide (Zepbound) is available from $299/month. That shifts patient expectations around what GLP-1 therapy “should” cost, which makes your ability to articulate the value of clinical oversight, not just the medication, more important than it was six months ago.

Monthly check-ins, side effect management, dietary guidance, and exercise accountability are the services that produce durable outcomes.

Choosing the right GLP-1 starts with the patient’s medical history

Not every patient should start on the same medication.

Given increased awareness around price expectations, patients are increasingly cost-conscious before they even walk in. That makes your first recommendation matter more, because it signals whether your clinic understands both their clinical needs and their financial reality.

Dr. Qayyum outlined a decision framework rooted in clinical history, patient preference, and cost.

For most patients without complicating conditions, she starts with compounded semaglutide. It has strong efficacy data, lower cost when compounded, and patients respond well when you communicate the price advantage directly.

Meanwhile, for patients with obstructive sleep apnea, tirzepatide (Mounjaro/Zepbound) may be the better first choice given its FDA approval for that indication and its dual mechanism of action.

For more specific recommendations, we recommend you check out Dr. Qayyum’s full presentation.

In the end, it’s individualization that matters. “Every patient is different,” Dr. Qayyum said. “It’s very customized. It’s patient dependent.” Your clinical judgment in matching the right drug to the right patient is precisely the value that no discount platform replicates.

Evitalin and our pharmacy partners offer compounded GLP-1 formulations across the current portfolio, giving you flexibility to match each patient to the right protocol without being locked into a single product.

Maintenance planning is the real clinical challenge

Most patients will regain some weight after stopping GLP-1 therapy. Dr. Qayyum was candid about this.

“If you come off a GLP-1, it is very likely you may gain the weight back. That’s the bottom line.”

Her solution is not indefinite high-dose prescribing. Once a patient reaches their goal weight, she tapers to the lowest effective dose and maintains them there long term. Monthly visits continue. Side effect monitoring continues. The clinical relationship continues.

“I’ve had patients who lost weight, came off, and kept the weight loss,” she said. “But you know why? Really good regimented diet and exercise protocols. Organized, disciplined.” She acknowledged that this describes a minority of patients.

Patients at maintenance who experience GI side effects at standard doses can reduce to half the minimum dose while preserving the appetite regulation that prevents regain.

Dr. Qayyum also cautioned against reducing injection frequency below weekly, noting that less-than-weekly dosing is likely ineffective.

This maintenance phase is where your practice builds long-term recurring revenue while delivering genuine clinical value. Memberships, maintenance plans, and ongoing monitoring create the kind of patient relationships that keep your practice sustainable.

A strong pharmacy partnership reduces your risk exposure

Compounded GLP-1 prescribing carries risk, particularly around sterile preparation, expiration date management, storage protocols, and patient education on injection technique.

“Make sure you have a protocol in place and you are educating your patients,” she said. “And the pharmacies, make sure it’s one that is legally able to compound these drugs and does it in a sterile and safe environment.”

Her advice was practical: document your protocols, train your staff, manage expiration dates carefully, and maintain open communication with your compounding pharmacy.

Patients should have a clear channel to reach a nurse or staff member with questions. The relationship between your clinic and your pharmacy is a direct line of defense against adverse events and the litigation that can follow.

“I like this pharmacy. They’re so good. They’re so helpful,” Dr. Qayyum said. “I can email them and immediately. I get very fast responses.”

Your account manager at Evitalin can connect you with our pharmacy partner’s pharmacist for formulation questions, dosing guidance, or protocol development. That support infrastructure exists to reduce the burden on your clinical team and protect your practice.

The expanding GLP-1 landscape

Retatrutide, a triple-acting GLP-1/GIP/glucagon receptor agonist from Eli Lilly, is progressing through clinical trials with results expected in 2026 and a potential FDA filing shortly after. If approved, it would add a third mechanism of action to the weight management toolkit. The oral Wegovy pill (semaglutide 25 mg), now FDA-approved and available as of January 2026, gives patients a once-daily alternative to weekly injections with comparable weight loss outcomes.

Meanwhile, pricing pressure continues to mount. TrumpRx now offers branded GLP-1 options starting at $149/month for the Wegovy pill and $199/month for Wegovy and Ozempic pens, with Zepbound starting at $299/month. That means your patients are paying closer attention to cost than ever. The comprehensive care model, where GLP-1 therapy is one component of a broader weight management and metabolic health program, is what differentiates your practice from discount platforms.

Interested in learning more about how to handle pricing questions from your patients, read this article.

Dr. Qayyum put it simply: “Please use it as an adjunctive therapy. Patient education is so important.”

The full workshop recording includes detailed dosing protocols, formulation comparisons, contraindication guidance, and the complete live Q&A covering topics from sulfur burps to surgical discontinuation timelines. Watch it to get the clinical details you need to prescribe with confidence.